ICP-248 in Combination With Orelabrutinib in Treatment-na ïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions: Hematologic Malignancies Interventions: Drug: ICP-248; Drug: Orelabrutinib Sponsors: Beijing InnoCare Pharma Tech Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials